PHILADELPHIA, PA--(Marketwired - Jan 27, 2015) - A mass tort litigation program was designated in the Philadelphia County Court of Common Pleas for lawsuits involving the blood thinner drug Xarelto and its link to potentially deadly bleeding events. Anapol Schwartz is now accepting cases on behalf of Xarelto users who were injured as well as families of those who died from uncontrollable bleeding while taking Xarelto.
The pending claims allege Xarelto manufacturers marketed the drug as a superior alternative to older anticoagulant drugs such as warfarin. But unlike warfarin, which can be reversed with vitamin K, there is currently no approved reversal agent to stop Xarelto users from bleeding.
On top of these dangers, Bayer HealthCare Pharmaceuticals and Johnson & Johnson's Janssen Pharmaceuticals failed to recommend blood monitoring for Xarelto patients to give physicians an opportunity to adjust dosage. Reduced medical monitoring of a patient's health means a problem could become catastrophic without any chance of professional intervention.
"The real world consequences of any drug must be clearly communicated to patients," said Anapol Schwartz Shareholder Gregory Spizer. Spizer serves in various leadership capacities in national mass tort litigation including Co-Lead Counsel in the New Jersey consolidated Mirena Litigation. He also successfully represented hundreds of clients in the $4.85 billion Vioxx settlement.
In addition to the mass tort program established in Philadelphia, Xarelto lawsuits filed in federal courts were consolidated into a multidistrict litigation in the Eastern District of Louisiana last month, according to court documents.
About Anapol Schwartz
Anapol Schwartz is national leader in pharmaceutical litigation, having successfully litigated thousands of cases during the last 30 years. The firm has obtained hundreds of millions of dollars in successful verdicts, settlements and judgments on behalf of its clients.
